CanagliflozinMeSH Descriptor

A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

https://www.has-sante.fr/jcms/p_3224377/fr/medicaments-du-diabete-de-type-2-la-has-actualise-son-evaluation-des-gliflozines
2021
false
false
false
France
French
drug evaluation
Sodium-Glucose Transporter 2 Inhibitors
diabetes mellitus, type 2
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
Canagliflozin
empagliflozin
empagliflozin
Canagliflozin
dapagliflozin
treatment outcome
diabetic cardiomyopathies
diabetic nephropathies
risk
continuity of patient care
drug monitoring
dapagliflozin

---
https://www.has-sante.fr/jcms/p_3218337/fr/invokana
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
Sodium-Glucose Transporter 2 Inhibitors
canagliflozin
Product containing precisely canagliflozin 300 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely canagliflozin 100 milligram/1 each conventional release oral tablet (clinical drug)
adult
diabetes mellitus, type 2
drug therapy, combination
metformin
insulin
Chronic kidney disease stage 2 due to type 2 diabetes mellitus (disorder)
Chronic kidney disease stage 3 due to type 2 diabetes mellitus (disorder)
guidelines for drug use
evaluation of the transparency committee
Invokana
Canagliflozin

---
https://www.louvainmedical.be/fr/article/la-canagliflozine-invokanar-est-associee-une-nephro-cardioprotection-exemplaire-dans-le
2019
false
false
false
Belgium
French
Canagliflozin
diabetes mellitus, type 2
cardiovascular diseases
diabetic nephropathies
treatment outcome
Sodium-Glucose Transporter 2 Inhibitors
renal insufficiency
journal article

---
https://www.usherbrooke.ca/baladocritique/archives/episode-25-etude-credence/
2019
false
false
false
Canada
Sodium-Glucose Transporter 2 Inhibitors
diabetes mellitus, type 2
prognosis
sound
Canagliflozin
diabetic nephropathies

---
https://www.revmed.ch/RMS/2017/RMS-N-565/Acidocetose-euglycemique-une-complication-des-inhibiteurs-du-SGLT2
2018
false
false
false
Switzerland
French
administration, oral
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Product containing sodium glucose cotransporter subtype 2 inhibitor (product)
SGLT2 Inhibitor
Sodium-Glucose transporter 2
Canagliflozin
hypoglycemic agents
empagliflozin
dapagliflozin
ketosis
journal article
practice guidelines as topic
precipitating factors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
benzhydryl compounds
glucosides

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/invokana-diabete-4389.html
2018
false
false
false
false
Canada
French
drug information
Canagliflozin
Invokana

---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2017/64366a-fra.php
2017
false
false
false
Canada
French
English
pharmacovigilance note
Canagliflozin
hypoglycemic agents
drug combinations
metformin
metformin and canagliflozin
canagliflozin
guidelines for drug use
risk factors
Amputation of lower limb (procedure)
lower extremity
Amputation, Surgical
diabetes mellitus, type 2
cardiovascular diseases
diabetes complications
Sodium-Glucose transporter 2
SGLT2 Inhibitor
lower extremity
continuity of patient care
Sodium-Glucose Transporter 2 Inhibitors

---
https://www.usherbrooke.ca/baladocritique/archives/episode-9-etude-canvas/
2017
false
true
false
false
Canada
French
sound
Canagliflozin
diabetes mellitus, type 2
cardiovascular risk
cardiovascular diseases
risk
kidney diseases
data collection
Canagliflozin
Mediastinal abscess
Diabetes mellitus type 2
kidney, nos
episode of
diabetes non-insulin dependent
diabetes mellitus, type 2
effective
glycosuria, renal

---
SGLT2 inhibitors
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-12-fra.php#sglt2
2016
false
false
false
Canada
French
English
drug evaluation
SGLT2 Inhibitor
Sodium-Glucose transporter 2
Canagliflozin
hypoglycemic agents
risk assessment
dapagliflozin
empagliflozin
diabetes mellitus, type 2
fractures, bone
bone demineralization, pathologic
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds

---
Invokana (canagliflozin) and Invokamet (canagliflozin and metformin hydrochloride)
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-12-page2-fra.php#invo
2016
false
false
false
Canada
French
English
pharmacovigilance note
Canagliflozin
diabetes mellitus, type 2
metformin and canagliflozin
drug combinations
hypoglycemic agents
Amputation, Surgical
risk assessment
toes
canagliflozin

---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58404a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
Sodium-Glucose transporter 2
SGLT2 Inhibitor
Canagliflozin
hypoglycemic agents
dapagliflozin
metformin and dapagliflozin
drug combinations
metformin
empagliflozin
diabetic ketoacidosis
guidelines for drug use
diabetes mellitus, type 2
risk factors
dapagliflozin
canagliflozin
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds

---
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Potential Risk of Bone-Related Side Effects
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/sglt2-3-fra.php
2016
false
false
false
Canada
French
English
Canagliflozin
hypoglycemic agents
dapagliflozin
Sodium-Glucose transporter 2
SGLT2 Inhibitor
risk assessment
drug evaluation
empagliflozin
adult
diabetes mellitus, type 2
fractures, bone
bone demineralization, pathologic
bone and bones
pharmacovigilance note
product surveillance, postmarketing
canada
dapagliflozin
canagliflozin
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
benzhydryl compounds
glucosides

---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/993
2014
false
false
false
false
Canada
French
critical appraisal or critical reading
glimepiride
glimepiride
treatment outcome
comparative effectiveness research
diabetes mellitus, type 2
administration, oral
hypoglycemic agents
hypoglycemic agents
Glycated Hemoglobin
metformin
blood glucose
Canagliflozin
Canagliflozin
sulfonylurea compounds
sulfonylurea compounds

---
http://www.has-sante.fr/portail/jcms/c_1776989/fr/invokana
http://www.has-sante.fr/portail/jcms/c_1776989/fr/invokana-canagliflozine
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
administration, oral
insurance, health, reimbursement
treatment outcome
adult
diabetes mellitus, type 2
hypoglycemic agents
Canagliflozin
canagliflozin
Product containing canagliflozin (medicinal product)

---
https://www.ema.europa.eu/medicines/human/EPAR/Vokanamet
2014
false
United Kingdom
French
English
drug combinations
drug approval
europe
treatment outcome
combinations of oral blood glucose lowering drugs
metformin
metformin
administration, oral
diabetes mellitus, type 2
hypoglycemic agents
hypoglycemic agents
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
aged
Sodium-Glucose transporter 2
summary of product characteristics
package leaflet
syndication feed
Canagliflozin
Canagliflozin
Sodium-Glucose Transporter 2 Inhibitors

---
Summary Basis of Decision (SBD) for Invokana
Canagliflozin, 100 mg and 300 mg , tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00255
2014
false
false
false
Canada
French
English
canada
drug approval
administration, oral
diabetes mellitus, type 2
drug therapy, combination
risk assessment
drug evaluation
treatment outcome
adult
hypoglycemic agents
hypoglycemic agents
Sodium-Glucose transporter 2
drug interactions
clinical trials, phase iii as topic
Canagliflozin
Canagliflozin
canagliflozin
drug information
Sodium-Glucose Transporter 2 Inhibitors
Product containing precisely canagliflozin 100 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely canagliflozin 300 milligram/1 each conventional release oral tablet (clinical drug)

---
http://www.has-sante.fr/portail/jcms/c_1776982/fr/vokanamet
http://www.has-sante.fr/portail/jcms/c_1776982/fr/vokanamet-canagliflozine/metformine
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
administration, oral
drug combinations
metformin and canagliflozin
metformin
hypoglycemic agents
treatment outcome
insurance, health, reimbursement
diabetes mellitus, type 2
adult
Canagliflozin

---
https://www.ema.europa.eu/medicines/human/EPAR/Invokana
2013
false
United Kingdom
French
English
adult
administration, oral
drug approval
europe
treatment outcome
diabetes mellitus, type 2
hypoglycemic agents
hypoglycemic agents
product surveillance, postmarketing
drug therapy, combination
package leaflet
summary of product characteristics
drug evaluation
syndication feed
aged
drug interactions
pregnancy
breast feeding
Sodium-Glucose transporter 2
SLC5A2 protein, human
drug evaluation, preclinical
drug evaluation
Canagliflozin
Canagliflozin
canagliflozin
Sodium-Glucose Transporter 2 Inhibitors
Product containing precisely canagliflozin 300 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely canagliflozin 100 milligram/1 each conventional release oral tablet (clinical drug)

---